- Veru Inc VERU reported a Q1 EPS loss of ($0.04), which met the analyst consensus estimate. The loss is wider than ($0.01) net loss a year ago.
- Sales for the quarter were reported at $13.3 million, up 34% Y/Y, but missed the analyst consensus estimate of $14.29 million.
- FC2 prescription net revenues from the U.S. prescription channel climbed 48% Y/Y to $10.3 million.
- Gross profit rose 47% Y/Y to $10.9 million, with a gross margin expansion to 82% from 75% last year.
- Operating loss was $1.5 million versus $0.3 million last year.
- Price Action: VERU shares are up 1.34% at $7.59 during the premarket session on the last check Wednesday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
